{"disease":{"id":"lymphatic-diseases","name":"lymphatic diseases"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05731141","title":"A Prospective Natural History Study of Lymphatic Anomalies","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT03744676","title":"A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"Juno Therapeutics, a Subsidiary of Celgene","has_results":true},{"nct_id":"NCT03373019","title":"Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":63,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03602157","title":"Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":43,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT02499627","title":"Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":43,"lead_sponsor_name":"Fondazione Italiana Linfomi - ETS","has_results":false},{"nct_id":"NCT02690545","title":"Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":38,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03709407","title":"\"Effects of Manual Lymphatic Drainage in the Neck in Healthy Subjects. Experimental Randomized Crossover Study\"","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Universidad Europea de Madrid","has_results":false},{"nct_id":"NCT03135535","title":"Micro-mobile Foot Compression and Diabetic Foot","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Baylor College of Medicine","has_results":true},{"nct_id":"NCT02335242","title":"Sildenafil for the Treatment of Lymphatic Malformations","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Stanford University","has_results":true},{"nct_id":"NCT03696784","title":"Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":19,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT05683444","title":"Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT03264131","title":"BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":16,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":true},{"nct_id":"NCT05263583","title":"Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":14,"lead_sponsor_name":"Cothera Bioscience, Inc","has_results":false},{"nct_id":"NCT05441943","title":"Lymphaticovenous Anastomosis as Treatment for Lymphedema","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Odense University Hospital","has_results":false},{"nct_id":"NCT06267807","title":"Lymphatic Phenotype in Noonan Syndrome Spectrum Disorders","phase":"NA","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT05145062","title":"Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8,"lead_sponsor_name":"Sangamo Therapeutics","has_results":false}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}